Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!
The investigation, which was initiated Sept. 26, reveals a number of shocking and serious safety deficiencies. They include:
• NECC distributed large batches of compounded sterile products directly to facilities apparently for general use rather than requiring a prescription for patients.
• Two different shipments of methylprednisolone acetate were delivered to providers before the NECC received final sterility test results in June and August.
• NECC failed to properly autoclave products to ensure product sterility.
• NECC failed to test their autoclaves to ensure proper function.
• Visible black particulate matter was found in several recalled vials of methylprednisolone acetate.
• Tacky mats, used to trap debris from shoes prior to clean room entry, were visibly soiled.
• A leaking boiler next to the clean room created a pool of water. Culture results from this pool are pending.
The health department’s investigation is ongoing. The NECC, which is subject to regulatory sanctions, permanently lost its license.
More Articles on Patient Safety:
FDA to List Providers Who Received NECC Products
Half of Americans Regret Choice of Physicians, Hospitals
AAAASF Names Dr. Geoffrey Keyes Board President
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
